111 related articles for article (PubMed ID: 27996101)
1. The Neutrophil-to-Lymphocyte Ratio Predicts All-Cause Mortality in Patients with Implantable Cardioverter Defibrillators.
Hashimoto N; Arimoto T; Narumi T; Iwayama T; Kutsuzawa D; Ishigaki D; Kumagai YU; Tamura H; Nishiyama S; Takahashi H; Shishido T; Miyamoto T; Watanabe T; Kubota I
Pacing Clin Electrophysiol; 2017 Feb; 40(2):135-144. PubMed ID: 27996101
[TBL] [Abstract][Full Text] [Related]
2. The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators.
Chen HA; Hsia HH; Vagelos R; Fowler M; Wang P; Al-Ahmad A
Pacing Clin Electrophysiol; 2007 Mar; 30(3):390-4. PubMed ID: 17367359
[TBL] [Abstract][Full Text] [Related]
3. Circulating heart-type fatty acid binding protein levels predict the occurrence of appropriate shocks and cardiac death in patients with implantable cardioverter-defibrillators.
Daidoji H; Arimoto T; Nitobe J; Tamura H; Kutsuzawa D; Ishigaki D; Ishino M; Takahashi H; Shishido T; Miyashita T; Miyamoto T; Watanabe T; Kubota I
J Card Fail; 2012 Jul; 18(7):556-63. PubMed ID: 22748489
[TBL] [Abstract][Full Text] [Related]
4. Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score.
Kraaier K; Scholten MF; Tijssen JG; Theuns DA; Jordaens LJ; Wilde AA; van Dessel PF
Europace; 2014 Jan; 16(1):40-6. PubMed ID: 23918791
[TBL] [Abstract][Full Text] [Related]
5. Differences in predictors of implantable cardioverter-defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies.
Darma A; Nedios S; Kosiuk J; Richter S; Doering M; Arya A; Rolf S; Sommer P; Hindricks G; Bollmann A
Europace; 2016 Mar; 18(3):405-12. PubMed ID: 26056190
[TBL] [Abstract][Full Text] [Related]
6. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
[TBL] [Abstract][Full Text] [Related]
7. The association between ICD interventions and mortality is independent of their modality: clinical implications.
Bencardino G; Di Monaco A; Rio T; Frontera A; Santangeli P; Leo M; Pelargonio G; Perna F; Narducci ML; Gabrielli F; Lanza GA; Bellocci F; Rebuzzi A; Crea F
J Cardiovasc Electrophysiol; 2014 Dec; 25(12):1363-7. PubMed ID: 25066621
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil to lymphocyte ratio predicts appropriate therapy in idiopathic dilated cardiomyopathy patients with primary prevention implantable cardioverter defibrillator.
Uçar FM; Açar B
Saudi Med J; 2017 Feb; 38(2):143-148. PubMed ID: 28133686
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
[TBL] [Abstract][Full Text] [Related]
11. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
[TBL] [Abstract][Full Text] [Related]
12. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory blood pressure monitoring, 2D-echo and clinical variables relating to cardiac events in ischaemic cardiomyopathy following cardioverter-defibrillator implantation.
Antonini L; Pasceri V; Mollica C; Ficili S; Poti G; Aquilani S; Santini M; La Rocca S
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):334-9. PubMed ID: 21487343
[TBL] [Abstract][Full Text] [Related]
15. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
[TBL] [Abstract][Full Text] [Related]
16. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
[TBL] [Abstract][Full Text] [Related]
17. Impact of renal function on survival in patients with implantable cardioverter-defibrillators.
Turakhia MP; Varosy PD; Lee K; Tseng ZH; Lee R; Badhwar N; Scheinman M; Lee BK; Olgin JE
Pacing Clin Electrophysiol; 2007 Mar; 30(3):377-84. PubMed ID: 17367357
[TBL] [Abstract][Full Text] [Related]
18. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
[TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
[TBL] [Abstract][Full Text] [Related]
20. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
